• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Tuesday's Pre-Market Session

    2/28/23 8:06:43 AM ET
    $ADMP
    $AHCO
    $APTX
    $AVGR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Nursing Services
    Health Care
    Get the next $ADMP alert in real time by email

    Gainers

    • Catalyst Biosciences (NASDAQ:CBIO) shares moved upwards by 59.1% to $0.38 during Tuesday's pre-market session. The market value of their outstanding shares is at $14.4 million.
    • eFFECTOR Therapeutics (NASDAQ:EFTR) stock moved upwards by 34.04% to $0.65. The company's market cap stands at $27.2 million.
    • Stereotaxis (AMEX:STXS) stock increased by 28.85% to $3.26. The company's market cap stands at $243.9 million.
    • Cardio Diagnostics Hldgs (NASDAQ:CDIO) stock increased by 26.61% to $1.69. The market value of their outstanding shares is at $16.0 million.
    • Adamis Pharmaceuticals (NASDAQ:ADMP) stock moved upwards by 22.73% to $0.32. The company's market cap stands at $48.5 million.
    • Comera Life Sciences (NASDAQ:CMRA) stock moved upwards by 18.86% to $1.45. The market value of their outstanding shares is at $32.2 million.

    Losers

    • Aptinyx (NASDAQ:APTX) shares decreased by 66.3% to $0.2 during Tuesday's pre-market session. The company's market cap stands at $13.4 million.
    • AdaptHealth (NASDAQ:AHCO) stock declined by 21.39% to $17.28. The company's market cap stands at $2.3 billion. As per the press release, Q4 earnings came out yesterday.
    • IsoPlexis (NASDAQ:ISO) stock declined by 8.0% to $0.92. The market value of their outstanding shares is at $37.1 million.
    • Avinger (NASDAQ:AVGR) shares declined by 7.41% to $1.0. The market value of their outstanding shares is at $7.4 million.
    • Cardiff Oncology (NASDAQ:CRDF) shares declined by 6.71% to $1.53. The company's market cap stands at $68.3 million.
    • Milestone Scientific (AMEX:MLSS) stock fell 6.39% to $0.71. The company's market cap stands at $49.5 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ADMP alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADMP
    $AHCO
    $APTX
    $AVGR

    CompanyDatePrice TargetRatingAnalyst
    Crescent Biopharma Inc.
    $CBIO
    1/28/2026$35.00Overweight
    Piper Sandler
    Crescent Biopharma Inc.
    $CBIO
    1/21/2026$35.00Buy
    Guggenheim
    Cardiff Oncology Inc.
    $CRDF
    1/5/2026$12.00Outperform
    Noble Capital Markets
    Stereotaxis Inc.
    $STXS
    12/16/2025$4.00Mkt Outperform
    Citizens JMP
    Crescent Biopharma Inc.
    $CBIO
    8/25/2025$26.00Buy
    Jefferies
    Crescent Biopharma Inc.
    $CBIO
    8/11/2025$25.00Buy
    H.C. Wainwright
    Crescent Biopharma Inc.
    $CBIO
    7/14/2025$27.00Outperform
    Wedbush
    Cardiff Oncology Inc.
    $CRDF
    7/8/2025$19.00Buy
    Ladenburg Thalmann
    More analyst ratings

    $ADMP
    $AHCO
    $APTX
    $AVGR
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for ZIMHI issued to ADAMIS PHARMS CORP

    Submission status for ADAMIS PHARMS CORP's drug ZIMHI (ORIG-1) with active ingredient NALOXONE HYDROCHLORIDE has changed to 'Approval' on 10/15/2021. Application Category: NDA, Application Number: 212854, Application Classification: Type 5 - New Formulation or New Manufacturer

    10/18/21 11:55:40 AM ET
    $ADMP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for SYMJEPI issued to ADAMIS PHARMS CORP

    Submission status for ADAMIS PHARMS CORP's drug SYMJEPI (SUPPL-12) with active ingredient EPINEPHRINE has changed to 'Approval' on 06/29/2021. Application Category: NDA, Application Number: 207534, Application Classification: Labeling

    6/30/21 5:11:48 AM ET
    $ADMP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADMP
    $AHCO
    $APTX
    $AVGR
    SEC Filings

    View All

    Stereotaxis Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

    8-K - Stereotaxis, Inc. (0001289340) (Filer)

    3/9/26 4:05:44 PM ET
    $STXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form EFFECT filed by Crescent Biopharma Inc.

    EFFECT - CRESCENT BIOPHARMA, INC. (0001253689) (Filer)

    3/4/26 12:15:05 AM ET
    $CBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form POS AM filed by Crescent Biopharma Inc.

    POS AM - CRESCENT BIOPHARMA, INC. (0001253689) (Filer)

    3/2/26 9:29:21 PM ET
    $CBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADMP
    $AHCO
    $APTX
    $AVGR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Piper Sandler initiated coverage on Crescent Biopharma with a new price target

    Piper Sandler initiated coverage of Crescent Biopharma with a rating of Overweight and set a new price target of $35.00

    1/28/26 7:10:21 AM ET
    $CBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Guggenheim initiated coverage on Crescent Biopharma with a new price target

    Guggenheim initiated coverage of Crescent Biopharma with a rating of Buy and set a new price target of $35.00

    1/21/26 8:54:45 AM ET
    $CBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Noble Capital Markets initiated coverage on Cardiff Oncology with a new price target

    Noble Capital Markets initiated coverage of Cardiff Oncology with a rating of Outperform and set a new price target of $12.00

    1/5/26 9:06:54 AM ET
    $CRDF
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADMP
    $AHCO
    $APTX
    $AVGR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Wolf Dale B bought $71,680 worth of shares (8,000 units at $8.96), increasing direct ownership by 8% to 104,235 units (SEC Form 4)

    4 - AdaptHealth Corp. (0001725255) (Issuer)

    3/3/26 6:41:28 PM ET
    $AHCO
    Medical/Nursing Services
    Health Care

    CLO and General Counsel Rew Richard W. Ii bought $44,550 worth of shares (5,000 units at $8.91), increasing direct ownership by 5% to 107,097 units (SEC Form 4)

    4 - AdaptHealth Corp. (0001725255) (Issuer)

    2/27/26 4:01:18 PM ET
    $AHCO
    Medical/Nursing Services
    Health Care

    Director Fairmount Funds Management Llc bought $18,237,600 worth of Ordinary Shares (1,360,000 units at $13.41) (SEC Form 4)

    4 - CRESCENT BIOPHARMA, INC. (0001253689) (Issuer)

    12/8/25 4:30:15 PM ET
    $CBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADMP
    $AHCO
    $APTX
    $AVGR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Weaver Susan T received a gift of 73,472 shares and gifted 73,472 shares, decreasing direct ownership by 77% to 21,346 units (SEC Form 4)

    4 - AdaptHealth Corp. (0001725255) (Issuer)

    3/9/26 9:14:51 PM ET
    $AHCO
    Medical/Nursing Services
    Health Care

    Director Wolf Dale B bought $71,680 worth of shares (8,000 units at $8.96), increasing direct ownership by 8% to 104,235 units (SEC Form 4)

    4 - AdaptHealth Corp. (0001725255) (Issuer)

    3/3/26 6:41:28 PM ET
    $AHCO
    Medical/Nursing Services
    Health Care

    CLO and General Counsel Rew Richard W. Ii bought $44,550 worth of shares (5,000 units at $8.91), increasing direct ownership by 5% to 107,097 units (SEC Form 4)

    4 - AdaptHealth Corp. (0001725255) (Issuer)

    2/27/26 4:01:18 PM ET
    $AHCO
    Medical/Nursing Services
    Health Care

    $ADMP
    $AHCO
    $APTX
    $AVGR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Stereotaxis Reports 2025 Full Year Financial Results

    ST. LOUIS, March 09, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the fourth quarter and full year ended December 31, 2025. "The past year saw tremendous progress with significant regulatory approvals globally, advancement of a broad pipeline of innovations, and revenue growth of over 20%. I'm proud of what our team has accomplished and excited for the year ahead," said David Fischel, Chairman and CEO. "The highlight of the past year was achieving regulatory approvals in the United States and Europe for the GenesisX robot, MAGiC ablation catheter, a

    3/9/26 4:01:00 PM ET
    $STXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Crescent Biopharma Announces Grants of Inducement Awards

    WALTHAM, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. ("Crescent" or the "Company") (NASDAQ:CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that the independent Compensation Committee of its Board of Directors approved the grant of options to purchase an aggregate of 45,675 shares of the Company's ordinary shares to two non-executive employees as equity inducement awards under the Crescent Biopharma, Inc. 2025 Employment Inducement Incentive Award Plan, as amended (the "Inducement Plan"). The options were approved on March 5, 2026 and were material to each employee's acceptanc

    3/6/26 4:15:00 PM ET
    $CBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cardiff Oncology to Participate in Three Upcoming Investor Conferences

    SAN DIEGO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will participate in three upcoming investor conferences in March 2026.   TD Cowen 46th Annual Health Care ConferenceDate: 03/04/26 Barclays 28th Annual Global Healthcare ConferenceDate: 03/10/26 Leerink Partners Global Healthcare Conference 2026Date: 03/11/26 Interested parties can register for and access the live webcast for the conferences by visiting the "Events" section of the Cardiff Oncology website. The webcast replay will be available afte

    2/26/26 4:01:00 PM ET
    $CRDF
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADMP
    $AHCO
    $APTX
    $AVGR
    Leadership Updates

    Live Leadership Updates

    View All

    Cardiff Oncology Announces Executive Leadership Changes as it Transitions to Late-Stage Clinical Development

    SAN DIEGO, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced a leadership transition designed to support the Company's next phase of growth and advancement toward late-stage development and key clinical and corporate milestones. Mani Mohindru, PhD, a member of Cardiff Oncology's Board of Directors since 2021 and a seasoned biotech executive, has been appointed interim Chief Executive Officer, effective immediately. Mark Erlander, PhD, Chief Executive Officer, and James Levine, Chief Financial Officer, have stepped down from their res

    1/27/26 7:00:00 AM ET
    $CRDF
    $CTMX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Milestone Scientific Appoints Dr. Dawood Sayed to Board of Directors to Advance Commercial and Clinical Strategy in Pain Management

    ROSELAND, N.J., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced the appointment of Dawood Sayed, M.D., a nationally recognized leader in interventional pain medicine, to its Board of Directors, effective immediately. Dr. Sayed is a Professor of Anesthesiology and Pain Medicine at the University of Kansas Medical Center and currently serves as Division Chief of Pain Medicine, Director of Interventional Spine Services, and Director of the Center for Neuromodulation. With a robust clinical, academic, and policy background, he brings over a deca

    9/22/25 9:15:00 AM ET
    $MLSS
    Industrial Specialties
    Health Care

    Stereotaxis Technology to be Featured at Heart Rhythm Society's HRX 2025

    ST. LOUIS, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced its technology will be featured during the upcoming HRX digital health conference taking place September 4-6, 2025, in Atlanta, Georgia. HRX, an initiative pioneered by the Heart Rhythm Society, is focused on exploring digital technologies that advance the frontiers of cardiovascular medicine. Stereotaxis CEO, David Fischel, will participate in a roundtable discussion on September 5th at 3:45 PM EDT. Later that day, at 4:45 PM EDT, a distinguished panel of electrophysiologists, including Dr. Daniel Cooper,

    8/28/25 7:47:00 AM ET
    $STXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ADMP
    $AHCO
    $APTX
    $AVGR
    Financials

    Live finance-specific insights

    View All

    Stereotaxis Reports 2025 Full Year Financial Results

    ST. LOUIS, March 09, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the fourth quarter and full year ended December 31, 2025. "The past year saw tremendous progress with significant regulatory approvals globally, advancement of a broad pipeline of innovations, and revenue growth of over 20%. I'm proud of what our team has accomplished and excited for the year ahead," said David Fischel, Chairman and CEO. "The highlight of the past year was achieving regulatory approvals in the United States and Europe for the GenesisX robot, MAGiC ablation catheter, a

    3/9/26 4:01:00 PM ET
    $STXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Cardiff Oncology Reports Full Year 2025 Results and Provides Business Update

    Reported positive update from Phase 2 CRDF-004 trial in first-line RAS-mutated mCRC, with the 30 mg onvansertib + FOLFIRI/bev arm demonstrating:• Robust ORR of 72.2% (vs 43.2% with combined SoC of FOLFOX/bev and FOLFIRI/bev)• Significant improvement in PFS over combined SoC (HR: 0.37, p<0.05) Data support selection of 30 mg onvansertib dose in combination with FOLFIRI/bev for planned registrational program; detailed data and registrational plans expected in the first half of 2026 SAN DIEGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today an

    2/24/26 4:30:00 PM ET
    $CRDF
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    AdaptHealth Corp. Announces Fourth Quarter and Full-Year 2025 Results and Provides 2026 Financial Guidance

    AdaptHealth Corp. (NASDAQ:AHCO) ("AdaptHealth" or the "Company"), a national leader in providing patient-centered, healthcare-at-home solutions including home medical equipment, medical supplies, and related services, announced today financial results for the fourth quarter and fiscal year ended December 31, 2025. Fourth Quarter Business Highlights Set patient census records for Sleep Health, Respiratory Health, and Wellness at Home, and a patient retention record for Diabetes Health. Acquired a leading HME provider in Hawaii, expanding the Company's geographic footprint to its 48th State and establishing operations to support the Company's new key capitated contract. Made signif

    2/24/26 7:00:00 AM ET
    $AHCO
    Medical/Nursing Services
    Health Care

    $ADMP
    $AHCO
    $APTX
    $AVGR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Avinger Inc.

    SC 13G - Avinger Inc (0001506928) (Subject)

    11/14/24 3:23:30 PM ET
    $AVGR
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by AdaptHealth Corp.

    SC 13G/A - AdaptHealth Corp. (0001725255) (Subject)

    11/14/24 9:03:31 AM ET
    $AHCO
    Medical/Nursing Services
    Health Care

    SEC Form SC 13G filed by AdaptHealth Corp.

    SC 13G - AdaptHealth Corp. (0001725255) (Subject)

    11/13/24 9:30:46 PM ET
    $AHCO
    Medical/Nursing Services
    Health Care